How does the CSL (ASX:CSL) share price perform during lockdowns?

As Australia remains locked down, how can we expect the ASX biotech share to perform?

| More on:
ResMed share price healthcare asx share price flat represented by doctor shrugging

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price edged 0.36% lower to close at $296.87 on Monday. Shares in the Aussie biotech have managed to climb higher so far in 2021 but have still underperformed the S&P/ASX 200 Index (ASX: XJO) thus far.

With vast swathes of Australia currently subject to tight COVID-19 restrictions, let's see how one of Australia's largest companies has changed in value throughout previous lockdowns.

What happens to the CSL share price during lockdowns?

Let's wind the clock back to February 2020. As COVID-19 spread across the world, most Aussie shares were in freefall in the March bear market. CSL was not immune from the downturn and fell 19.5% from 20 February to 20 March.

The CSL share price largely recovered and hit $329.00 per share by April 2020. Since then, however, share price growth has been subdued.

Let's consider recent lockdowns and how the ASX biotech share has performed in those times. For instance, Melbourne was subject to strict lockdown orders from August to October 2020.

The ASX biotech share did manage to climb 6.5% from the start of August to the end of October. It's easy to think then that the CSL share price performs strongly during lockdowns.

However, this period also coincided with CSL announcing a vaccine partnership with the University of Queensland. While lockdowns can be extensive, there can also be many company-specific or macro events that impact share prices during those times.

Sydney's Northern Beaches outbreak started just before Christmas last year. The CSL share price fell 4.8% lower throughout the month of December to close the year at $283.18.

Once again, however, the scrapping of the CSL/University of Queensland vaccine candidate occurred on 12 December and may have had a large impact on the share price.

What about the current Sydney outbreak?

While there have been shorter lockdowns in Perth, Adelaide and Melbourne in the intervening months, let's take a look at the current outbreak in Sydney. The first case in the current outbreak was recorded on 16 June with lockdown restrictions from 24 June.

The CSL share price fell 9.8% from 21 June to 15 July. However, the ASX biotech share is up 7.9% since then to its current $296.87 per share level.

Foolish takeaway

For many companies, it's hard to find direct correlations between share price movements and lockdown restrictions. That's particularly the case for a company as large and varied as CSL, which also has a stake in the COVID-19 effort through its AstraZeneca production contract.

The CSL share price growth has been subdued in 2021. Shares in the Aussie biotech are up 4.16% year to date and 6.21% in the last 12 months. Investors will be watching closely to see where they are headed amid the current eastern seaboard lockdowns.

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Healthcare Shares

Guess which ASX 200 stock is jumping 16% on big news

Let's find out what news is getting investors excited this afternoon.

Read more »

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »